Vanguard Portfolio Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
DPCM
Vanguard Portfolio Management's PCRX Position: Q2 2026 in Review
Vanguard Portfolio Management reduced its Pacira BioSciences (PCRX) stake by 3.8% in Q2 2026, selling an estimated $2.25M and leaving 2,406,238 shares worth $61M. The position accounts for ﹤0.01% of the portfolio, ranked #1662.
Vanguard Portfolio Management first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 252 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- Vanguard Portfolio Management held 2,406,238 shares of Pacira BioSciences worth $61M as of Q2 2026.
- Vanguard Portfolio Management sold 95,048 Pacira BioSciences shares in Q2 2026, an estimated $2.25M.
- Pacira BioSciences made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1662 holding.
- Vanguard Portfolio Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
- 252 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.